nach oben

Erschienen in:

01.08.2013 | Review Article

Rational for statin use in psoriatic patients

verfasst von: Jerzy Mosiewicz, Aldona Pietrzak, Grażyna Chodorowska, Marcin Trojnar, Jacek Szepietowski, Kristian Reich, Manfredi Rizzo

Erschienen in: Archives of Dermatological Research | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Psoriasis represents a common skin disease which is clinically manifested by chronic cutaneous lesions. It has been observed that psoriasis is associated with an increased risk of cardiovascular diseases, which is contributed to the inappropriate lipid metabolism. Statins are commonly used in clinical practice to lower cholesterol concentration and, accordingly, decrease the individual risk of developing a cardiovascular episode. There have been reports that statin administration could also result in better management of psoriasis. The observed beneficial effects are contributed to the effects on lipid metabolism, including that in skin, as well as anti-inflammatory and immunomodulatory properties of statins. Simvastatin and atorvastatin were found to improve the clinical outcome in patients with psoriatic skin lesions. Clinically, the effectiveness of this novel treatment was confirmed by the significant reduction in PASI score. To date several cases have been reported in which atorvastatin or pravastatin worsened psoriasis. Based on these results, it seems that statins represent a promising class of medications which could be extensively used in psoriasis.

Aronson PJ, Friedman DB (1992) Pharmacologic doses of lovastatin do not predictably affect the course of psoriasis. Arch Dermatol 128(1):124PubMedCrossRef

Beller GA (2008) What can be learned from the COURAGE trial? J Nucl Cardiol 15:1–2PubMedCrossRef

Bellosta S, Paoletti R, Corsini A (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109(23 Suppl 1):III50–III57PubMed

Boehncke WH, Boehncke S, Schön MP (2010) Managing comorbid disease in patients with psoriasis. BMJ 340:b5666PubMedCrossRef

Brauchli YB, Jick SS, Meier CR (2011) Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol 65:77–83PubMedCrossRef

Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610–621PubMedCrossRef

Cozzani E, Scaparro M, Parodi A (2009) A case of psoriasis worsened by atorvastatin. J Dermatol Case Rep 3:60–61PubMed

Duncan RE, El-Sohemy A, Archer MC (2005) Statins and cancer development. Can Epidemiol Biom Prev 14(8):1897–1898CrossRef

Egesi A, Sun G, Khachemoune A, Rashid RM (2010) Statins in skin: research and rediscovery, from psoriasis to sclerosis. J Drugs Dermatol 9(8):921–927PubMed

10.

Faghihi T, Radfar M, Mehrabian Z, Ehsani AH, Rezaei Hemami M (2011) Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy 31:1045–1050PubMedCrossRef

11.

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef

12.

Ghazizadeh R, Tosa M, Ghazizadeh M (2011) Clinical improvement in psoriasis with treatment of associated hyperlipidemia. Am J Med Sci 341(5):394–398PubMedCrossRef

13.

Gottlieb AB, Dann F (2009) Comorbidities in patients with psoriasis. Am J Med 122:1150–1159PubMedCrossRef

14.

Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF (2012) NF-κB: an essential transcription factor in psoriasis. J Dermatol Sci 69(2):89–94PubMedCrossRef

15.

Greenwood J, Steinman L, Zamvil SS (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6:358–370PubMedCrossRef

16.

Gressier L, Pruvost-Balland C, Dubertret L, Viguier M (2009) Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol 136:50–53PubMedCrossRef

17.

Grip O, Janciauskiene S, Bredberg A (2008) Use of atorvastatin as an anti-inflammatory treatment in Crohn’s disease. Br J Pharmacol 155:1085–1092PubMedCrossRef

18.

Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosch W, Tillmanns W et al (2003) Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 41(2003):397–401PubMed

19.

Jacobi TC, Highet A (2003) A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol 149:1305–1306PubMedCrossRef

20.

Jowkar F, Namazi MR (2010) Statins in dermatology. Int J Dermatol 49(11):1235–1243PubMedCrossRef

21.

Kim N, Thrash B, Menter A (2010) Comorbidities in psoriasis patients. Semin Cutan Med Surg 29:10–15PubMedCrossRef

22.

Kim TG, Byamba D, Wu WH, Lee MG (2011) Statins inhibit chemotactic interaction between CCL20 and CCR6 in vitro: possible relevance to psoriasis treatment. Exp Dermatol 20(10):855–857PubMedCrossRef

23.

Kwatra SG (2011) Statins differ significantly in their anti-inflammatory activity. J Am Acad Dermatol 65(6):1229 Author reply 1229–30PubMedCrossRef

24.

Lin SL, Chien CW, Han CL, Chen ES, Kao SH, Chen YJ, Liao F (2010) Temporal proteomics profiling of lipid rafts in CCR6-activated T cells reveals the integration of actin cytoskeleton dynamics. J Proteome Res 9:283–297PubMedCrossRef

25.

Montanaro S, Lhiaubet-Vallet V, Iesce MI, Previtera L, Miranda MA (2009) A mechanistic study on the phototoxicity of atorvastatin: singlet oxygen generation by a phenanthrene-like photoproduct. Chem Res Toxicol 22:173–178PubMedCrossRef

26.

Naldi L (2004) Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 3:121–128PubMedCrossRef

27.

Namazi MR (2004) Statins: novel additions to the dermatologic arsenal? Exp Dermatol 13(6):337–339PubMedCrossRef

28.

Naseri M, Hadipour A, Sepaskhah M, Namazi MR (2010) The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med 19:58–61PubMed

29.

Noël B (2007) Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 21(1):17–24PubMedCrossRef

30.

Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370(9602):1829–1839PubMedCrossRef

31.

Qi XF, Kim DH, Yoon YS, Li JH, Jin D, Teng YC et al (2009) Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-γ in HaCaT cells, a human keratinocyte cell line. Br J Pharmacol 157:1441–1450PubMedCrossRef

32.

Raychaudhuri SP, Farber EM (2001) The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 15:16–17PubMedCrossRef

33.

Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N et al (2011) Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 164(4):862–872PubMedCrossRef

34.

Reiter M, Wirth S, Pourazim A, Baghestanian M, Minar E, Bucek RA (2005) Statin therapy has no significant effect on skin tissue cholesterol: results from a prospective randomized trial. Clin Chem 51:252–254PubMedCrossRef

35.

Rizzo M, Spinas GA, Rini GB, Berneis K (2010) Is diabetes the cost to pay for a greater cardiovascular prevention? Int J Cardiol 144(2):309–310PubMedCrossRef

36.

Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117–125PubMedCrossRef

37.

Schmutz JL, Barbaud A, Tréchot P (2008) Effets secondaires cutanés des bstatines. Ann Dermatol Venereol 135:253–254PubMedCrossRef

38.

Shirinsky IV, Shirinsky VS (2007) Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol 57(3):529–531PubMedCrossRef

39.

Späh F (2008) Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159(Suppl 2):10–17PubMedCrossRef

40.

Tablazon IL, Al-Dabagh A, Davis SA, Feldman SR (2013) Risk of cardiovascular disorders in psoriasis patients: current and future. Am J Clin Dermatol 14(1):1–7PubMedCrossRef

41.

Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289:1681–1690PubMedCrossRef

42.

Tapon N, Hall A (1997) Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol 9(1):86–92PubMedCrossRef

43.

Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP et al (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1:CD004816PubMed

44.

Vasiuk IuA, Perlamutrov IuN, Shkol’nik MN, Shkol’nik EL (2010) Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension. Kardiologiia 50(3):37–46PubMed

45.

Waehre T, Damås JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE et al (2003) Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 41:1460–1467PubMedCrossRef

46.

Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C et al (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687–692PubMedCrossRef

47.

Yamamoto M, Ikeda M, Kodama H, Sano S (2008) Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. J Dermatol 35:732–736PubMedCrossRef

Titel: Rational for statin use in psoriatic patients
verfasst von: Jerzy Mosiewicz
Aldona Pietrzak
Grażyna Chodorowska
Marcin Trojnar
Jacek Szepietowski
Kristian Reich
Manfredi Rizzo
Publikationsdatum: 01.08.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Dermatological Research / Ausgabe 6/2013
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-013-1374-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Rational for statin use in psoriatic patients

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

The relationship between severity of the disease and circulating nucleosomes in psoriasis patients

The role of systemic use of methotrexate on the oxidative stress in patients with psoriasis should be evaluated with a randomized controlled trial

Serum prolidase activity in psoriasis patients

Serum prolidase may not accurately provide information to clinicians about the psoriasis activity

X-rays and photocarcinogenesis in hairless mice

High association of angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism with recurrent aphthous stomatitis

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie